• Eun Jin Kim, Sun Ha Choi, Jae Seok Park, Yong Shik Kwon, Jaehee Lee, Yeonjae Kim, Shin Yup Lee, and Eun Young Choi.
• Division of Pulmonary and Critical Care Medicine, Daegu Catholic University Medical Center, Daegu, Korea.
• Yonsei Med. J. 2020 Sep 1; 61 (9): 826-830.

AbstractWe retrospectively reviewed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections who were admitted to an intensive care unit in Daegu, South Korea. The outcomes of patients who did (cases) or did not (controls) receive darunavir-cobicistat (800-150 mg) therapy were compared. Fourteen patients received darunavir-cobicistat treatment, and 96 received other antiviral therapy (controls). Overall, the darunavir-cobicistat group comprised patients with milder illness, and the crude mortality rate of all patients in the darunavir-cobicistat group was lower than that in the controls [odds ratio (OR) 0.20, 95% confidence interval (CI) 0.04-0.89, p=0.035]. After 1:2 propensity-score matching, there were 14 patients in the darunavir-cobicistat group, and 28 patients in the controls. In propensity score-matched analysis, the darunavir-cobicistat group had lower mortality than the controls (OR 0.07, 95% CI 0.01-0.52, p=0.009). In conclusion, darunavir-cobicistat therapy was found to be associated with a significant survival benefit in critically ill patients with SARS-CoV-2 infection.© Copyright: Yonsei University College of Medicine 2020.

44 keywords...

hide…